[
  {
    "ts": null,
    "headline": "Why Analysts Say Akamai Technologies (AKAM) Story Is Shifting Toward Security Compute And AI",
    "summary": "The recent shift in Akamai Technologies' fair value estimate to US$101.16 from US$95.20 reflects updated assumptions around how its push into security, compute, and AI infrastructure might influence the long term outlook. With the discount rate trimmed to 10.21% and revenue growth now modeled at 6.99%, the revised target remains in the same ballpark as recent Street work that clusters around the US$100 to US$115 range, but still embeds a mix of optimism and caution about the investment needed...",
    "url": "https://finnhub.io/api/news?id=ed476061e08b753bb728d511368e5baac9936736c222104de23269ab0952d498",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768929005,
      "headline": "Why Analysts Say Akamai Technologies (AKAM) Story Is Shifting Toward Security Compute And AI",
      "id": 138188520,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "The recent shift in Akamai Technologies' fair value estimate to US$101.16 from US$95.20 reflects updated assumptions around how its push into security, compute, and AI infrastructure might influence the long term outlook. With the discount rate trimmed to 10.21% and revenue growth now modeled at 6.99%, the revised target remains in the same ballpark as recent Street work that clusters around the US$100 to US$115 range, but still embeds a mix of optimism and caution about the investment needed...",
      "url": "https://finnhub.io/api/news?id=ed476061e08b753bb728d511368e5baac9936736c222104de23269ab0952d498"
    }
  },
  {
    "ts": null,
    "headline": "Vertical Software Well Positioned to Monetize AI Growth, Morgan Stanley Says",
    "summary": "Vertical software companies with wide proprietary industry data sets and end-to-end platforms are we",
    "url": "https://finnhub.io/api/news?id=11cd247444f5b0e7dd6ef57e51d9929f327f74cff371f6bb5b694b5e613fc474",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768928185,
      "headline": "Vertical Software Well Positioned to Monetize AI Growth, Morgan Stanley Says",
      "id": 138188521,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "Vertical software companies with wide proprietary industry data sets and end-to-end platforms are we",
      "url": "https://finnhub.io/api/news?id=11cd247444f5b0e7dd6ef57e51d9929f327f74cff371f6bb5b694b5e613fc474"
    }
  },
  {
    "ts": null,
    "headline": "Participation notifications by Morgan Stanley",
    "summary": "Press release Regulated information Brussels, January 20, 2026, 17:45 CET In line with Belgian transparency legislation (Law of May 2, 2007), Morgan Stanley recently sent to Solvay the following transparency notifications indicating that they crossed the threshold of 3%. Here is a summary of the notifications: Date on which the threshold is crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotalDecember 23, 20250.00%-0.00%January 9, 20260.04%3.16%3.2",
    "url": "https://finnhub.io/api/news?id=69d313fa70c7f8d65a0f6ebcd681b8b58d3645b54a8724c5c1aa7e434ad3f6c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768927500,
      "headline": "Participation notifications by Morgan Stanley",
      "id": 138188522,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "Press release Regulated information Brussels, January 20, 2026, 17:45 CET In line with Belgian transparency legislation (Law of May 2, 2007), Morgan Stanley recently sent to Solvay the following transparency notifications indicating that they crossed the threshold of 3%. Here is a summary of the notifications: Date on which the threshold is crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotalDecember 23, 20250.00%-0.00%January 9, 20260.04%3.16%3.2",
      "url": "https://finnhub.io/api/news?id=69d313fa70c7f8d65a0f6ebcd681b8b58d3645b54a8724c5c1aa7e434ad3f6c7"
    }
  },
  {
    "ts": null,
    "headline": "Why Hims & Hers Health (HIMS) Stock Is Down Today",
    "summary": "Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2.2% in the morning session after Morgan Stanley reiterated its Equalweight rating but voiced concerns about the company's slowing growth and increasing competition.",
    "url": "https://finnhub.io/api/news?id=69c4ee41c9e98bafaa42806dbd91b2d46554946e53980f7271d8d454beffe62f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768926352,
      "headline": "Why Hims & Hers Health (HIMS) Stock Is Down Today",
      "id": 138188523,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2.2% in the morning session after Morgan Stanley reiterated its Equalweight rating but voiced concerns about the company's slowing growth and increasing competition.",
      "url": "https://finnhub.io/api/news?id=69c4ee41c9e98bafaa42806dbd91b2d46554946e53980f7271d8d454beffe62f"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley sees improving fundamentals driving small-cap outperformance",
    "summary": "Investing.com -- Morgan Stanley told clients in a recent note that improving fundamentals continue to support small-cap equity outperformance, even as the market pares back expectations for Federal Reserve rate cuts this year.",
    "url": "https://finnhub.io/api/news?id=7baf14200e4aec06344e7a007d15d5f598a6b6226a3f446e0bc33f64be9314db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768925729,
      "headline": "Morgan Stanley sees improving fundamentals driving small-cap outperformance",
      "id": 138188524,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "Investing.com -- Morgan Stanley told clients in a recent note that improving fundamentals continue to support small-cap equity outperformance, even as the market pares back expectations for Federal Reserve rate cuts this year.",
      "url": "https://finnhub.io/api/news?id=7baf14200e4aec06344e7a007d15d5f598a6b6226a3f446e0bc33f64be9314db"
    }
  },
  {
    "ts": null,
    "headline": "Celanese's Q4 Earnings Likely to Hit Low End of Guidance Amid Acetyl Margin Pressure, Morgan Stanley Says",
    "summary": "Celanese's (CE) earnings per share for Q4 of 2025 is expected to be at the low end of its guidance d",
    "url": "https://finnhub.io/api/news?id=61ff73b397419ce5563fa2964abf4f18a613f6425ca3ce84d982f8c08491a75f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768923985,
      "headline": "Celanese's Q4 Earnings Likely to Hit Low End of Guidance Amid Acetyl Margin Pressure, Morgan Stanley Says",
      "id": 138187493,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "Celanese's (CE) earnings per share for Q4 of 2025 is expected to be at the low end of its guidance d",
      "url": "https://finnhub.io/api/news?id=61ff73b397419ce5563fa2964abf4f18a613f6425ca3ce84d982f8c08491a75f"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Real Estate Investing Acquires San Francisco Bay Area Advanced Manufacturing Facility for $110 Million",
    "summary": "NEW YORK, January 20, 2026--Morgan Stanley Investment Management, through funds managed by Morgan Stanley Real Estate Investing (MSREI), announced today the acquisition of a premier advanced manufacturing property in Fremont, California, for $110 million, which is subject to a long-term net lease with Western Digital, a global leader in the data storage and infrastructure solutions sector.",
    "url": "https://finnhub.io/api/news?id=98b4b760c4ab25cf1d264c02f2d78c58037011f7ede9496475a073150bb8f5cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768917600,
      "headline": "Morgan Stanley Real Estate Investing Acquires San Francisco Bay Area Advanced Manufacturing Facility for $110 Million",
      "id": 138187494,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "NEW YORK, January 20, 2026--Morgan Stanley Investment Management, through funds managed by Morgan Stanley Real Estate Investing (MSREI), announced today the acquisition of a premier advanced manufacturing property in Fremont, California, for $110 million, which is subject to a long-term net lease with Western Digital, a global leader in the data storage and infrastructure solutions sector.",
      "url": "https://finnhub.io/api/news?id=98b4b760c4ab25cf1d264c02f2d78c58037011f7ede9496475a073150bb8f5cb"
    }
  },
  {
    "ts": null,
    "headline": "US IT hardware stocks fall as Morgan Stanley turns cautious on sector",
    "summary": "U.S. IT hardware stocks fell on Tuesday after Morgan Stanley downgraded its view on the ​industry, warning that companies could drastically reduce their spending ‌budgets as enterprise demand slows and component costs rise. U.S.-listed shares of Logitech ‌and NetApp dropped 6.2% and about 3.8% respectively in premarket trading after the Wall Street brokerage slashed its rating on both companies to \"underweight\" from \"equal-weight\". Morgan Stanley reduced its rating on CDW Corporation to \"equal-weight\" ⁠from \"overweight\", sending its shares ‌down 2.1%.",
    "url": "https://finnhub.io/api/news?id=8c08d6f2ce8922f0aa16fb0737f316204cc33bdd045a29d84cf40c74683c98f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768908160,
      "headline": "US IT hardware stocks fall as Morgan Stanley turns cautious on sector",
      "id": 138185707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "U.S. IT hardware stocks fell on Tuesday after Morgan Stanley downgraded its view on the ​industry, warning that companies could drastically reduce their spending ‌budgets as enterprise demand slows and component costs rise. U.S.-listed shares of Logitech ‌and NetApp dropped 6.2% and about 3.8% respectively in premarket trading after the Wall Street brokerage slashed its rating on both companies to \"underweight\" from \"equal-weight\". Morgan Stanley reduced its rating on CDW Corporation to \"equal-weight\" ⁠from \"overweight\", sending its shares ‌down 2.1%.",
      "url": "https://finnhub.io/api/news?id=8c08d6f2ce8922f0aa16fb0737f316204cc33bdd045a29d84cf40c74683c98f9"
    }
  },
  {
    "ts": null,
    "headline": "How Recent Analyst Shifts Are Rewriting The Story For Clorox (CLX)",
    "summary": "Clorox’s latest price target work reflects a slightly more cautious base case, with fair value trimmed from about US$122.41 to US$119.76 as analysts balance mixed views on volume, pricing, and earnings quality. The discount rate and long term revenue growth assumptions are essentially steady, but modestly softer expectations for the top line and earnings power have been enough to nudge the fair value estimate lower rather than higher. If you are following the stock, it is worth staying tuned...",
    "url": "https://finnhub.io/api/news?id=ae528bfcde2e1d77c2f17c2f00a559d0e8ee849766652c86e4ea6d11b81c03df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768907051,
      "headline": "How Recent Analyst Shifts Are Rewriting The Story For Clorox (CLX)",
      "id": 138185697,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "Clorox’s latest price target work reflects a slightly more cautious base case, with fair value trimmed from about US$122.41 to US$119.76 as analysts balance mixed views on volume, pricing, and earnings quality. The discount rate and long term revenue growth assumptions are essentially steady, but modestly softer expectations for the top line and earnings power have been enough to nudge the fair value estimate lower rather than higher. If you are following the stock, it is worth staying tuned...",
      "url": "https://finnhub.io/api/news?id=ae528bfcde2e1d77c2f17c2f00a559d0e8ee849766652c86e4ea6d11b81c03df"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley (MS)’s CEO is Doing a Great Job, Says Jim Cramer",
    "summary": "We recently published 15 Fresh Stocks Jim Cramer Discussed. Morgan Stanley (NYSE:MS) is one of the stocks Jim Cramer discussed. Morgan Stanley (NYSE:MS) is one of the largest investment banks in the world. The shares are up by 37% over the past year and by 3.9% year-to-date. Keefe Bruyette raised the share price target to […]",
    "url": "https://finnhub.io/api/news?id=381c292b185dd4fcd716af428e8f4877aec794fc441626a990206468f8fc7f89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768906918,
      "headline": "Morgan Stanley (MS)’s CEO is Doing a Great Job, Says Jim Cramer",
      "id": 138185709,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "We recently published 15 Fresh Stocks Jim Cramer Discussed. Morgan Stanley (NYSE:MS) is one of the stocks Jim Cramer discussed. Morgan Stanley (NYSE:MS) is one of the largest investment banks in the world. The shares are up by 37% over the past year and by 3.9% year-to-date. Keefe Bruyette raised the share price target to […]",
      "url": "https://finnhub.io/api/news?id=381c292b185dd4fcd716af428e8f4877aec794fc441626a990206468f8fc7f89"
    }
  },
  {
    "ts": null,
    "headline": "Akamai Technologies’ Quarterly Earnings Preview: What You Need to Know",
    "summary": "Akamai Technologies is poised to release its fourth-quarter results next month, with analysts anticipating a modest single-digit decline in earnings.",
    "url": "https://finnhub.io/api/news?id=f5aa346cbda09a62b174c1f2387db34a25e20d638de3972015772b71a4ee9c06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768906425,
      "headline": "Akamai Technologies’ Quarterly Earnings Preview: What You Need to Know",
      "id": 138186473,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "Akamai Technologies is poised to release its fourth-quarter results next month, with analysts anticipating a modest single-digit decline in earnings.",
      "url": "https://finnhub.io/api/news?id=f5aa346cbda09a62b174c1f2387db34a25e20d638de3972015772b71a4ee9c06"
    }
  },
  {
    "ts": null,
    "headline": "Looking At The Narrative For Alector (ALEC) After Latozinemab Setback And Cost Cuts",
    "summary": "The fair value estimate for Alector has shifted slightly, moving from 2.05 to 2.10, while the discount rate has also adjusted from 7.54% to 7.39%, even as the revenue growth assumption remains anchored to about a 50.08% decline. This reflects a recalibrated view after mixed Street research, where cautious ratings, the failed latozinemab Phase 3 trial, and a pipeline reset sit alongside cost cuts and remaining pipeline options that some investors still factor into their thinking. Continue with...",
    "url": "https://finnhub.io/api/news?id=3414be98e8abfd27cbe26af3e829a9c65d9d72ba4f33baa1ce14831287d6b6e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768867861,
      "headline": "Looking At The Narrative For Alector (ALEC) After Latozinemab Setback And Cost Cuts",
      "id": 138181945,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "The fair value estimate for Alector has shifted slightly, moving from 2.05 to 2.10, while the discount rate has also adjusted from 7.54% to 7.39%, even as the revenue growth assumption remains anchored to about a 50.08% decline. This reflects a recalibrated view after mixed Street research, where cautious ratings, the failed latozinemab Phase 3 trial, and a pipeline reset sit alongside cost cuts and remaining pipeline options that some investors still factor into their thinking. Continue with...",
      "url": "https://finnhub.io/api/news?id=3414be98e8abfd27cbe26af3e829a9c65d9d72ba4f33baa1ce14831287d6b6e8"
    }
  }
]